溶栓胶囊对高原红细胞增多症凝血纤溶系统的影响  

Effcet of Rongshuanjiaonang on Fibrinolysis Coagulation System in High Altitude Polycythemia Patients

作　　者：雷应权[1] 符中明[1] 冯国君[1] 任雨笙[2] 彭顺舟[1] 王东平[1] 

机构地区：[1]解放军第41医院检验病理科,西藏山南856000 [2]上海第二军医大学长征医院心内科,200003

出　　处：《医药导报》2004年第5期311-312,共2页Herald of Medicine

摘　　要：目的:研究溶栓胶囊对高原红细胞增多症(HAPC)凝血纤溶系统的影响。方法:治疗组HAPC患者32例,口服溶栓胶囊2粒,bid,疗程1个月,检测患者服药前后血浆组织型纤溶酶原激活剂(t-PA)、纤溶酶原激活药抑制物(PAI-1)活性和凝血因子Ⅰ含量,并以健康的移居34例进行对比,不用任何药物。结果:汉族男性服药1个月后患者t-PA活性升高(1.53±0.23)u·mL^(-1)(P<0.05),PAI活性降低(0.66±0.10)u·mL^(-1)(P<0.05),Fbg含量降低(2.23±0.78)g·L^(-1)(P<0.05)。结论:溶栓胶囊可有效改善高原红细胞增多症患者血液凝血纤溶系统功能。Objective: To study the effect of rongshuanjiaonang on fibrinolysis coagulation system in high altitude polycythemia (HAPC) patients. Methods: Thirty-two HAPC patients as the treatment group took two capsules of rongshuanjiaonang twice daily for 1 mo. And tissue-type plasminogen activator (t-PA), plasminogen activator inhibior-1 (PAI-1), fibrinongen (Fbg) in the plasma were checked before and after the study while thirty-four health immigrants took nothing as the control. Results: The values of t-PA, PAI-1, and Fbg changed from (0.64±0.17) U·mL^(-1), (1.48±0.24) AU·mL^(-1), (4.55±1.21) g·L^(-1) to (1.53±0.23) U·mL^(-1), (0.66±0.10) AU·mL^(-1), and (1.53±0.23) U·mL^(-1). By comparison, t-PA, PAI-1, and Fbg were significantly changed in the HAPC patients (P<0.05). Conclusion: Rongshuanjiaonang can improve function of fibrinolysis coagulation system in HAPC patients.

关 键 词：溶栓胶囊 红细胞增多症/高原 凝血纤溶系统 

分 类 号：R286[医药卫生—中药学] R555.1[医药卫生—中医学]